Drugs

New opioid treatment programs highlight 'forgotten epidemic'

Retrieved on: 
Friday, January 8, 2021
Opioids, Psychoactive drugs, Drugs, Morphinans, Substance dependence, Morphine, Euphoriants, Alcohol abuse, Drug rehabilitation, Addiction, Heroin, Opioid epidemic in the United States

In Phoenix, the CMS facility will open its doors 24 hours per day, 7 days per week, and provide all 3 FDA-approved medications for opioid addiction treatment.

Key Points: 
  • In Phoenix, the CMS facility will open its doors 24 hours per day, 7 days per week, and provide all 3 FDA-approved medications for opioid addiction treatment.
  • CMS is the first OTP agency in the country to open 24/7 Opioid Treatment on Demand centers (OTOD).
  • And that means expanding access to treatment to those who are suffering from addictions to opioids and other illicit substances."
  • "We understand that when those suffering from an opioid use disorder make the decision to seek treatment, time is of the essence," Stavros said.

Worldwide Industry for Botulinum Toxin to 2024 - Escalating Number of Plastic Surgeons is Driving Growth

Retrieved on: 
Thursday, January 7, 2021
Drugs, Botulism, Botulinum toxin, Neurotoxins, Toxins, Toxicology

The report provides a detailed regional analysis of the US, Europe, Japan, Asia (excluding Japan), Korea and China for the botulinum toxin market.

Key Points: 
  • The report provides a detailed regional analysis of the US, Europe, Japan, Asia (excluding Japan), Korea and China for the botulinum toxin market.
  • Growth of the overall global botulinum toxin market has also been forecasted for the period 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
  • The competition in the global botulinum toxin market is stiff and dominated by big players like Allergan.
  • The major growth drivers for the botulinum toxin market are: ageing population, escalating numbers of surgeons, upsurge in facial aesthetics procedures, rising alternative of non-surgical procedures, increasing healthcare spending in emerging markets.

Global ADC (Antibody Drug Conjugates) Contract Manufacturing Markets, 2020-2030: Current Scenario and Future Potential & Capabilities of Contract Services Providers

Retrieved on: 
Thursday, January 7, 2021
Drugs, Breakthrough therapy, Polatuzumab vedotin, Life sciences, Health sciences

The report offers a comprehensive study of the current scenario and future potential of the ADC contract manufacturing market.

Key Points: 
  • The report offers a comprehensive study of the current scenario and future potential of the ADC contract manufacturing market.
  • The study features an in-depth analysis, highlighting the capabilities of contract services providers engaged in this domain.
  • Some of the recently approved ADC therapeutics include BLENREP (2020), TRODELVYTM (2020), PadcevTM (2019) and POLIVY (2019).
  • Given the anticipated growth in demand for ADCs, the contract manufacturing market in this domain is anticipated to witness substantial growth in the coming years.

ARJ Infusion Services Begins Monoclonal Antibody Infusion Treatments for High-Risk and COVID-19 Patients

Retrieved on: 
Thursday, January 7, 2021
Science, Seniors, Research, Pharmaceutical, Nursing, Health, Infectious diseases, Consumer, Health sciences, Bamlanivimab, Coronavirus disease, Pharmacy, Ice, Drugs, Medical research

ARJ Infusion Services will dispense and administer bamlanivimab, a monoclonal antibody drug to treat COVID-19.

Key Points: 
  • ARJ Infusion Services will dispense and administer bamlanivimab, a monoclonal antibody drug to treat COVID-19.
  • ARJ will dispense treatments to eligible high-risk individuals residing or working in assisted living and long-term care facilities.
  • ARJ is on the frontlines of the COVID-19 pandemic to serve patients with rare and severe chronic conditions, said Andy Copeland, Chief Executive Officer of ARJ Infusion Services.
  • ARJ Infusion Services is a nationwide industry leader in specialty pharmacy and in-home nursing services for children and adults with rare and chronic conditions.

Global and Chinese Dexamethasone Acetate Industry Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 7, 2021
Chemicals, Plastics, Manufacturing, Glucocorticoids, Drugs, COVID-19, COVID-19 drug development, Dexamethasone, Otologicals, Pregnanes, Economy of China, Market research, Organ systems, Chemistry

The "Global and Chinese Dexamethasone Acetate Industry, 2021 Market Research Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global and Chinese Dexamethasone Acetate Industry, 2021 Market Research Report" report has been added to ResearchAndMarkets.com's offering.
  • The 'Global and Chinese Dexamethasone Acetate Industry, 2021 Market Research Report' is a professional and in-depth study on the current state of the global Dexamethasone Acetate industry with a focus on the Chinese market.
  • Through statistical analysis, the report depicts the global and Chinese total market of Dexamethasone Acetate industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.
  • Overall, the report provides an in-depth insight of the 2021 global and Chinese Dexamethasone Acetate industry covering all important parameters.

Dexamethasone Market - Global Industry Perspective Comprehensive Analysis and Forecast, 2020-2026: The Rise of Dexamethasone as a Lifesaving Treatment for Critically Ill COVID-19 Patients - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 7, 2021
Health, Pharmaceutical, COVID-19, COVID-19 drug development, Dexamethasone, Organofluorides, Otologicals, Pregnanes, Drugs, Chemistry, Organic compounds

The "Dexamethasone Market By Formulation type, By Application, and End user - Global Industry Perspective Comprehensive Analysis and Forecast, 2020-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dexamethasone Market By Formulation type, By Application, and End user - Global Industry Perspective Comprehensive Analysis and Forecast, 2020-2026" report has been added to ResearchAndMarkets.com's offering.
  • The report covers forecast and analysis for the Dexamethasone market on a global and regional level.
  • Additionally, the report includes the study of opportunities available in the Dexamethasone market on a global as well as regional level.
  • The report provides company market share analysis in order to give a broader overview of the key players in the Dexamethasone market.

World Dexamethasone Consumption Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 7, 2021
Health, Pharmaceutical, COVID-19, COVID-19 drug development, Dexamethasone, Organofluorides, Otologicals, Pregnanes, Drugs, Spreadsheet, Chemistry, Organic compounds

The "CAS Dexamethasone World Consumption Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CAS Dexamethasone World Consumption Report" report has been added to ResearchAndMarkets.com's offering.
  • This CAS Dexamethasone World Consumption Report provides data on the net consumption of CAS 50-02-2 - Dexamethasone Substance(s) in each of the countries listed.
  • The CAS Dexamethasone World Consumption Reports gives 6 pages of data for each of about 200 countries, plus thousands of database tables and spreadsheets.
  • This product provides users with commercial intelligence on Dexamethasone markets and industries about 200 countries.

C21 Announces Divestment of Non-Core Assets in Oregon

Retrieved on: 
Thursday, January 7, 2021
Euphoriants, Entheogens, Medicinal plants, Psychoactive drugs, Branches of biology, Appetite stimulants, Herbalism, Drugs, Cannabis, Hash oil, Hemp, Tetrahydrocannabinol

Additional C$4.7 million in warrants exercised

Key Points: 
  • C21 Investments is a vertically integrated cannabis company that cultivates, processes, and distributes quality cannabis and hemp-derived consumer products in the United States.
  • The Company owns Silver State Relief and Silver State Cultivation in Nevada, and Phantom Farms, Swell Companies, Eco Firma Farms, and Pure Green in Oregon.
  • These brands produce and distribute a broad range of THC and CBD products from cannabis flowers, pre-rolls, cannabis oil, vaporizer cartridges and edibles.
  • Based in Vancouver, Canada, additional information on C21 Investments can be found at www.sedar.com and www.cxxi.ca .

CBD of Denver Inc. (CBDD) Engages Swiss and US Independent Auditors

Retrieved on: 
Thursday, January 7, 2021
Drugs, Euphoriants, Entheogens, Medicinal plants, Psychoactive drugs, Branches of biology, Herbalism, Appetite stimulants, Cannabidiol, Hemp, Cannabis, Medical cannabis

Denver, Colorado--(Newsfile Corp. - January 7, 2021) - CBD of Denver, Inc. (OTC: CBDD), a full-line CBD and Hemp oil company ("CBDD") and a producer and distributor of Cannabis and CBD products in Switzerland today announces they have signed an agreement with two accountants.

Key Points: 
  • Denver, Colorado--(Newsfile Corp. - January 7, 2021) - CBD of Denver, Inc. (OTC: CBDD), a full-line CBD and Hemp oil company ("CBDD") and a producer and distributor of Cannabis and CBD products in Switzerland today announces they have signed an agreement with two accountants.
  • CBD of Denver, Inc. (OTC: CBDD) a full-line CBD and Hemp oil company ("CBDD") and a producer and distributor of Cannabis and CBD products in Switzerland, Europe and the US.
  • CBDD offers a superior CBD product that is full spectrum without depending on THC to activate the benefits of cannabidiols.
  • Black Pearl CBD has 0% THC, but is not an Isolate where the THC is stripped from the product rendering it ineffective.

Fallon Health Partners With RX Savings Solutions

Retrieved on: 
Thursday, January 7, 2021
Health sciences, Health, Pharmaceuticals policy, Pharmacy, Healthcare reform in the United States, Drugs, Managed care, Medicare, Prescription drug, Fallon Health

OVERLAND PARK, Kan., Jan. 7, 2021 /PRNewswire/ -- Fallon Health , a nationally recognized not-for-profit health care services organization, has partnered with Rx Savings Solutions , the market leader tool for pharmacy transparency that enables more cost effective decision making, to help their eligible Medicare Advantage members save money on prescription drugs.

Key Points: 
  • OVERLAND PARK, Kan., Jan. 7, 2021 /PRNewswire/ -- Fallon Health , a nationally recognized not-for-profit health care services organization, has partnered with Rx Savings Solutions , the market leader tool for pharmacy transparency that enables more cost effective decision making, to help their eligible Medicare Advantage members save money on prescription drugs.
  • Serving more than 8 million members, Rx Savings Solutions' clinical engine contains over 30,000 unique and dose-adjusted suggestions, used to drive proven savings results for health plans and their members.
  • "We are delighted to partner with Fallon Health and provide their Medicare Advantage population with a platform that offers proactive prescription advice that delivers the best health and benefits experience at the lowest cost," said Michael Rea, a clinical pharmacist who founded and currently leads Rx Savings Solutions.
  • Rx Savings Solutions offers an innovative, patented engagement software system empowering employers and employees to be educated consumers of healthcare.